In pentavalent utilizing recombinant DNA and genetic engineering, we have developed robust prokaryotic and eukaryotic  expression platforms. Our expertise in purifying  proteins and mastering protein purification enables us to create high-quality diagnostic raw materials. Since 2020, we have established platforms for monoclonal antibody development using hybridoma technology, we have mastered the conjugation platform using colloidal gold, HRP, FITC, Latex beads to provide end to end solutions.

 Our innovative diagnostic raw materials for HIV, HCV, Syphillis, HBsAg and Dengue are designed for ELISA, colloidal gold and fluorophore testing platforms.

Pentavalent is committed to further diversifying its range of raw materials. We are continuously investing in R&D projects to meet the evolving demands of general health management and market trends. Our future offerings will include new and optimized products such as Malaria, cTnI, cTnT, Influenza A, Influenza B, CRP, Typhoid, Leishmaniasis, Filariasis, Leptospirosis, Scrub Typhus, cytokines, growth factors, and enzymes.